Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9809)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 27, 2014 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014; 6(8): 601-612 [PMID: 25232453 DOI: 10.4254/wjh.v6.i8.601] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v6/i8/601.htm |
| Number | Citing Articles |
| 1 |
Franziska Wewering, Florent Jouy, Dirk K. Wissenbach, Scarlett Gebauer, Matthias Blüher, Rolf Gebhardt, Ralph Pirow, Martin von Bergen, Stefan Kalkhof, Andreas Luch, Sebastian Zellmer. Characterization of chemical-induced sterile inflammation in vitro: application of the model compound ketoconazole in a human hepatic co-culture system. Archives of Toxicology 2017; 91(2): 799 doi: 10.1007/s00204-016-1686-y
|
| 2 |
Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti. Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”. Clinical Pharmacokinetics 2015; 54(4): 447 doi: 10.1007/s40262-015-0248-4
|
| 3 |
Patrizia Haegler, Lorenz Joerin, Stephan Krähenbühl, Jamal Bouitbir. Hepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents. Toxicological Sciences 2017; 157(1): 183 doi: 10.1093/toxsci/kfx029
|
| 4 |
David J. Greenblatt. The Pharmacovigilance Syndrome. Journal of Clinical Psychopharmacology 2015; 35(4): 361 doi: 10.1097/JCP.0000000000000367
|
| 5 |
Gemma Hayes, Lilyann Novak-Frazer. Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?. Journal of Fungi 2016; 2(2): 18 doi: 10.3390/jof2020018
|
| 6 |
Lydia L. Benitez, Peggy L. Carver. Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents. Drugs 2019; 79(8): 833 doi: 10.1007/s40265-019-01127-8
|
| 7 |
Meng Zhu, Linghui Tao, Feiye Zhu, Yongsheng Zhang. A Comparative Analysis of ADRs under Obeticholic Acid and
Ursodeoxycholic Acid in Cholestatic Liver Diseases Using the FAERS
Database. Drug Research 2024; 74(09): 464 doi: 10.1055/a-2401-4700
|
| 8 |
Emanuel Raschi, Fabrizio De Ponti. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World Journal of Hepatology 2015; 7(13): 1761-1771 doi: 10.4254/wjh.v7.i13.1761
|
| 9 |
Matheus Alexandre Da Silva Taliari, Andressa Costa Fontes, Fellipe Genasculi Araujo, Luis Lênin Vicente Pereira, Luciana Estevam Simonato, José Martins Pinto Neto, André Wilian Lozano, Nilton Cesar Pezati Boer, Wagner Rafael Da Silva, Rafael Guerra De Aquino, Farid Jamil Silva De Arruda, Fábio Zanusso Prates, Noedi Leoni De Freitas, Jean Donizete Silveira Taliari, Rogério Rodrigo Ramos. Protoporphyrin IX Associated with Visible Light for the Treatment of Trichophyton rubrum Causing Onychomycosis - An Updated Review. International Journal for Innovation Education and Research 2022; 10(6): 84 doi: 10.31686/ijier.vol10.iss6.3774
|
| 10 |
Zhi-Xuan Zhou, Xue-Dong Yin, Yu Zhang, Qi-Hui Shao, Xin-Yu Mao, Wen-Juan Hu, Yun-Lin Shen, Bin Zhao, Zhi-Ling Li. Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.891336
|
| 11 |
Qiang Shi, Xi Yang, James J. Greenhaw, Alec Thomas Salminen, Gary M. Russotti, William F. Salminen. Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status. International Journal of Toxicology 2017; 36(5): 365 doi: 10.1177/1091581817721675
|
| 12 |
Aditya K. Gupta, Kelly A. Foley, Sarah G. Versteeg. New Antifungal Agents and New Formulations Against Dermatophytes. Mycopathologia 2017; 182(1-2): 127 doi: 10.1007/s11046-016-0045-0
|
| 13 |
Andreas H Groll, Bart J A Rijnders, Thomas J Walsh, Jill Adler-Moore, Russell E Lewis, Roger J M Brüggemann. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical Infectious Diseases 2019; 68(Supplement_4): S260 doi: 10.1093/cid/ciz076
|
| 14 |
Noémi Outeiro, Nicolas Hohmann, Gerd Mikus. No Increased Risk of Ketoconazole Toxicity in Drug–Drug Interaction Studies. The Journal of Clinical Pharmacology 2016; 56(10): 1203 doi: 10.1002/jcph.795
|
| 15 |
Mohamed Kadry Taher, Abdallah Alami, Christopher A. Gravel, Derek Tsui, Lise M. Bjerre, Franco Momoli, Donald R. Mattison, Daniel Krewski. Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system. JGH Open 2021; 5(7): 778 doi: 10.1002/jgh3.12585
|
| 16 |
Nikolaos Spernovasilis, Diamantis P. Kofteridis. Pre-Existing Liver Disease and Toxicity of Antifungals. Journal of Fungi 2018; 4(4): 133 doi: 10.3390/jof4040133
|
| 17 |
Zainab M. Mahdi, Uta Synal-Hermanns, Aylin Yoker, Kaspar P. Locher, Bruno Stieger. Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis. Molecular Pharmacology 2016; 90(1): 23 doi: 10.1124/mol.116.103390
|
| 18 |
Emilie Faway, Cindy Staerck, Célya Danzelle, Sophie Vroomen, Christel Courtain, Bernard Mignon, Yves Poumay. Towards a Standardized Procedure for the Production of Infective Spores to Study the Pathogenesis of Dermatophytosis. Journal of Fungi 2021; 7(12): 1029 doi: 10.3390/jof7121029
|
| 19 |
Madhura Roy, Sonali Karhana, Md Shamsuzzaman, Mohd. Ashif Khan. Recent drug development and treatments for fungal infections. Brazilian Journal of Microbiology 2023; 54(3): 1695 doi: 10.1007/s42770-023-00999-z
|
| 20 |
Harshad Devarbhavi, Herbert L. Bonkovsky, Mark Russo, Naga Chalasani. Zakim and Boyer's Hepatology. 2018; : 844 doi: 10.1016/B978-0-323-37591-7.00056-2
|
| 21 |
Aditya K. Gupta, Rachel R. Mays, Sarah G. Versteeg, Neil H. Shear, Vincent Piguet. Update on current approaches to diagnosis and treatment of onychomycosis. Expert Review of Anti-infective Therapy 2018; 16(12): 929 doi: 10.1080/14787210.2018.1544891
|
| 22 |
Nadim Khalil, Jennifer L Kasten, Rebecca A Marsh, Lara Danziger-Isakov. Multifocal Trichosporon asahii Infection in a Patient With Chronic Granulomatous Disease. Journal of the Pediatric Infectious Diseases Society 2022; 11(10): 467 doi: 10.1093/jpids/piac064
|
| 23 |
David J. Greenblatt. Evidence‐based choice of ritonavir as index CYP3A inhibitor in drug‐drug interaction studies. The Journal of Clinical Pharmacology 2016; 56(2): 152 doi: 10.1002/jcph.609
|
| 24 |
David J. Greenblatt, Gerd Mikus. Ketoconazole and Liver Injury: A Five‐Year Update. Clinical Pharmacology in Drug Development 2019; 8(1): 6 doi: 10.1002/cpdd.652
|
| 25 |
Rachel Gallant, Phillip Bonney, Leigh Peek, Zhongxin Yu, David Crawford. Voriconazole‐induced hepatotoxicity following the administration of PEG‐asparaginase: Case report. Pediatric Blood & Cancer 2017; 64(6) doi: 10.1002/pbc.26293
|
| 26 |
Mohamed Kadry Taher, Abdallah Alami, Christopher A. Gravel, Derek Tsui, Lise M. Bjerre, Franco Momoli, Donald Mattison, Daniel Krewski. Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system. Expert Opinion on Drug Safety 2022; 21(2): 269 doi: 10.1080/14740338.2022.1993187
|
| 27 |
Andrea M. Burden, Lucy Hausammann, Alessandro Ceschi, Hugo Kupferschmidt, Stefan Weiler. Observational cross-sectional case study of toxicities of antifungal drugs. Journal of Global Antimicrobial Resistance 2022; 29: 520 doi: 10.1016/j.jgar.2021.11.010
|
| 28 |
Alicia Moreno‐Sabater, Nacéra Ouali, François Chasset, Camille Frances, Patricia Senet, Caroline Faucon, Christophe Hennequin, Claude Bachmeyer. Severe onychomycosis management with oral terbinafine in a kidney transplantation setting: Clinical follow‐up by image analysis. Mycoses 2021; 64(3): 309 doi: 10.1111/myc.13220
|
| 29 |
Maria Clara Padovani de Souza, Andrezza Gouvêa dos Santos, Adriano Max Moreira Reis. Adverse Drug Reactions in Patients Receiving Systemic Antifungal Therapy at a High‐Complexity Hospital. The Journal of Clinical Pharmacology 2016; 56(12): 1507 doi: 10.1002/jcph.772
|
| 30 |
A.K. Gupta, J. Carviel, M.A. MacLeod, N. Shear. Assessing finasteride‐associated sexual dysfunction using theFAERSdatabase. Journal of the European Academy of Dermatology and Venereology 2017; 31(6): 1069 doi: 10.1111/jdv.14223
|
| 31 |
Harshad Devarbhavi. Acute Liver Failure Induced by Anti-infectious Drugs: Causes and Management. Current Hepatology Reports 2017; 16(4): 276 doi: 10.1007/s11901-017-0367-5
|
| 32 |
Frank P. Tverdek, Diamantis Kofteridis, Dimitrios P. Kontoyiannis. Antifungal agents and liver toxicity: a complex interaction. Expert Review of Anti-infective Therapy 2016; 14(8): 765 doi: 10.1080/14787210.2016.1199272
|
| 33 |
Nancy H.C. Loos, Jos H. Beijnen, Alfred H. Schinkel. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomedicine & Pharmacotherapy 2023; 162: 114636 doi: 10.1016/j.biopha.2023.114636
|
| 34 |
Viktorija O. Barr, Elizabeth G. Zdyb, Michael Postelnick. The Clinical Significance of Azole Antifungals’ Effects on the Liver and Transaminase Levels. Current Fungal Infection Reports 2015; 9(3): 190 doi: 10.1007/s12281-015-0226-1
|
| 35 |
Felix Bongomin, Isabel Rodriguez-Goncer, Carol Lorden, Akaninyene Otu, Rohit Bazaz. Late-onset isavuconazole-induced liver injury. Medical Mycology Case Reports 2018; 22: 11 doi: 10.1016/j.mmcr.2018.07.006
|
| 36 |
Amin Rakhshan, Bardia Rahmati Kamel, Ali Saffaei, Maria Tavakoli-Ardakani. Hepatotoxicity Induced by Azole Antifungal Agents: A Review Study. Iranian Journal of Pharmaceutical Research 2023; 22(1) doi: 10.5812/ijpr-130336
|
| 37 |
B.S. Navarro, M.E. Auler, R.L.O. Dos Santos, L. da Silva Ruiz, D.C. Nascimento, P.A.N. Felippe, C. Domaneschi, D. Moreira, F.A. Baroni, M.F.C. Pires, C.R. Paula. Antifungal sensitivity and species of yeasts in oral mucosa of street mixed-breed dogs. Journal de Mycologie Médicale 2020; 30(4): 101010 doi: 10.1016/j.mycmed.2020.101010
|
| 38 |
Adam Lavertu, Bianca Vora, Kathleen M. Giacomini, Russ Altman, Stefano Rensi. A New Era in Pharmacovigilance: Toward Real‐World Data and Digital Monitoring. Clinical Pharmacology & Therapeutics 2021; 109(5): 1197 doi: 10.1002/cpt.2172
|
| 39 |
Rose O’Flynn, Yun-Ping Zhou, Hetty Waskin, Ronald Leong, Walter Straus. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer’s safety database. Expert Opinion on Drug Safety 2022; 21(8): 1113 doi: 10.1080/14740338.2022.2047177
|
| 40 |
Robert John Fontana, Elizabeth Theresa Cirulli, Jiezhun Gu, David Kleiner, David Ostrov, Elizabeth Phillips, Ryan Schutte, Huiman Barnhart, Naga Chalasani, Paul Brent Watkins, Jay H. Hoofnagle. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. Journal of Hepatology 2018; 69(6): 1317 doi: 10.1016/j.jhep.2018.08.004
|
| 41 |
Tim Bühler, Michael Medinger, Jamal Bouitbir, Stephan Krähenbühl, Anne Leuppi-Taegtmeyer. Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.00645
|
| 42 |
Payal Rana, Michael D. Aleo, Xuerong Wen, Stephen Kogut. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms. Acta Pharmaceutica Sinica B 2021; 11(12): 3857 doi: 10.1016/j.apsb.2021.05.028
|
| 43 |
M.A. Gupta, B. Vujcic, A.D. Sheridan, A.K. Gupta. Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the US FDA Adverse Events Reporting System pharmacovigilance database. Journal of the European Academy of Dermatology and Venereology 2020; 34(7): 1564 doi: 10.1111/jdv.16224
|
| 44 |
Peymaan S. Banankhah, Kyle A. Garnick, David J. Greenblatt. Ketoconazole‐Associated Liver Injury in Drug‐Drug Interaction Studies in Healthy Volunteers. The Journal of Clinical Pharmacology 2016; 56(10): 1196 doi: 10.1002/jcph.711
|
| 45 |
Emanuel Raschi, Elisabetta Poluzzi, Ariola Koci, Francesco Salvo, Antoine Pariente, Maurizio Biselli, Ugo Moretti, Nicholas Moore, Fabrizio De Ponti. Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system. British Journal of Clinical Pharmacology 2015; 80(2): 285 doi: 10.1111/bcp.12611
|
| 46 |
Emilie Faway, Marc Thiry, Bernard Mignon, Yves Poumay. Dermatophytes and Dermatophytoses. 2021; : 135 doi: 10.1007/978-3-030-67421-2_7
|
| 47 |
Fatma Etgü. Retrospective Analysis of Liver Enzyme Abnormalities in Patients Prescribed Terbinafine and Itraconazole for Onychomycosis . Cureus 2023; doi: 10.7759/cureus.44914
|
| 48 |
Jackson Thomas, Gregory M. Peterson, Julia K. Christenson, Sam Kosari, Kavya E. Baby. Antifungal Drug Use for Onychomycosis. American Journal of Therapeutics 2019; 26(3): e388 doi: 10.1097/MJT.0000000000000696
|
| 49 |
Özge AKÇAY, Mukaddes GÜMÜŞTEKİN. Voriconazole-Induced Hepatotoxicity Concise up-to-date review. Journal of Basic and Clinical Health Sciences 2022; 6(1): 325 doi: 10.30621/jbachs.1051669
|
| 50 |
Ioannis Kyriakidis, Athanasios Tragiannidis, Silke Munchen, Andreas H. Groll. Clinical hepatotoxicity associated with antifungal agents. Expert Opinion on Drug Safety 2016; : 1 doi: 10.1080/14740338.2017.1270264
|
| 51 |
A.K. Gupta, J. Carviel, M.A. Gupta, N.H. Shear. Assessing dutasteride‐associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System. Journal of the European Academy of Dermatology and Venereology 2018; 32(8): 1373 doi: 10.1111/jdv.14728
|
| 52 |
Aditya K. Gupta, Sarah G. Versteeg, Neil H. Shear. Confirmatory Testing Prior to Initiating Onychomycosis Therapy Is Cost-Effective. Journal of Cutaneous Medicine and Surgery 2018; 22(2): 129 doi: 10.1177/1203475417733461
|
| 53 |
Ippazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, Trond Riise, Kjetil Bjornevik, Elisa Baldin, Luigi Muratori, Fabrizio De Ponti, Emanuel Raschi. Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Multiple Sclerosis Journal 2019; 25(12): 1633 doi: 10.1177/1352458518799598
|
| 54 |
Bhavana Rajbanshi, Liangliang Shen, Miao Jiang, Qingyu Gao, Xin Huang, Jiaoyang Ma, Jihong Wang, Yang Hu, Hongli Lv, Xiao Wu, Jingjun Zhao. Comparative Study of Traditional Ablative CO2 Laser-Assisted Topical Antifungal with only Topical Antifungal for Treating Onychomycosis: A Multicenter Study. Clinical Drug Investigation 2020; 40(6): 575 doi: 10.1007/s40261-020-00914-6
|
| 55 |
David J. Greenblatt, Jerold S. Harmatz. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450‐3A in drug–drug interaction studies. British Journal of Clinical Pharmacology 2015; 80(3): 342 doi: 10.1111/bcp.12668
|
| 56 |
Miriam T. Levine, Pranatharthi H. Chandrasekar. Adverse effects of voriconazole: Over a decade of use. Clinical Transplantation 2016; 30(11): 1377 doi: 10.1111/ctr.12834
|
| 57 |
Romeo-Gabriel Mihăilă. Voriconazole and the liver. World Journal of Hepatology 2015; 7(14): 1828-1833 doi: 10.4254/wjh.v7.i14.1828
|
| 58 |
Vincent Lo Re, Dena M. Carbonari, James D. Lewis, Kimberly A. Forde, David S. Goldberg, K. Rajender Reddy, Kevin Haynes, Jason A. Roy, Daohang Sha, Amy R. Marks, Jennifer L. Schneider, Brian L. Strom, Douglas A. Corley. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. The American Journal of Medicine 2016; 129(3): 283 doi: 10.1016/j.amjmed.2015.10.029
|